BrainXell Therapeutics focuses on advancing brain health through innovative therapeutic solutions. The company is dedicated to personalizing treatments that target various neurological conditions, leveraging cutting-edge research and development to enhance patient outcomes. Their approach emphasizes the importance of understanding individual patient needs and tailoring therapies accordingly, which is crucial in the field of neuroscience.

The technologies employed by BrainXell include advanced cellular and molecular techniques aimed at developing effective treatments for brain-related disorders. By utilizing state-of-the-art methodologies, the company aims to create therapies that not only address symptoms but also target the underlying causes of neurological diseases. This commitment to personalized medicine positions BrainXell at the forefront of therapeutic innovation in the realm of brain health.

United States

BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry.

BrainXell

Company Details